Cambiar Investors LLC Has $13.75 Million Stake in Quest Diagnostics Incorporated (NYSE:DGX)

Cambiar Investors LLC lessened its stake in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 5.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 88,579 shares of the medical research company's stock after selling 4,770 shares during the quarter. Cambiar Investors LLC owned 0.08% of Quest Diagnostics worth $13,752,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in DGX. Rothschild Investment LLC acquired a new stake in shares of Quest Diagnostics in the 2nd quarter valued at about $26,000. Innealta Capital LLC acquired a new stake in Quest Diagnostics in the 2nd quarter valued at approximately $31,000. Larson Financial Group LLC lifted its stake in Quest Diagnostics by 77.5% in the 2nd quarter. Larson Financial Group LLC now owns 229 shares of the medical research company's stock valued at $31,000 after acquiring an additional 100 shares in the last quarter. TruNorth Capital Management LLC bought a new stake in Quest Diagnostics in the 2nd quarter valued at approximately $33,000. Finally, EdgeRock Capital LLC acquired a new position in Quest Diagnostics during the 2nd quarter worth approximately $35,000. Institutional investors own 88.06% of the company's stock.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 1,775 shares of Quest Diagnostics stock in a transaction on Monday, October 28th. The stock was sold at an average price of $156.92, for a total transaction of $278,533.00. Following the completion of the sale, the senior vice president now owns 9,734 shares of the company's stock, valued at approximately $1,527,459.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.79% of the company's stock.

Quest Diagnostics Stock Performance

DGX stock traded up $0.46 during midday trading on Friday, reaching $155.29. 1,094,683 shares of the company were exchanged, compared to its average volume of 922,014. Quest Diagnostics Incorporated has a one year low of $123.04 and a one year high of $160.95. The firm has a market capitalization of $17.33 billion, a price-to-earnings ratio of 20.87, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89. The business has a 50-day moving average price of $153.45 and a two-hundred day moving average price of $145.75. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.25 and a quick ratio of 1.17.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $2.30 EPS for the quarter, beating analysts' consensus estimates of $2.26 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.25%. The business had revenue of $2.49 billion for the quarter, compared to analyst estimates of $2.43 billion. During the same quarter in the prior year, the business earned $2.22 EPS. Quest Diagnostics's quarterly revenue was up 8.5% on a year-over-year basis. Equities research analysts forecast that Quest Diagnostics Incorporated will post 8.9 EPS for the current year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, October 21st. Investors of record on Friday, October 4th were paid a $0.75 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $3.00 annualized dividend and a yield of 1.93%. Quest Diagnostics's dividend payout ratio (DPR) is presently 40.32%.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Baird R W raised shares of Quest Diagnostics from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, October 23rd. Barclays increased their price objective on shares of Quest Diagnostics from $154.00 to $168.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 23rd. Citigroup lifted their target price on Quest Diagnostics from $165.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, October 23rd. StockNews.com raised Quest Diagnostics from a "hold" rating to a "buy" rating in a research report on Thursday. Finally, UBS Group boosted their price target on Quest Diagnostics from $165.00 to $166.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 23rd. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $164.58.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.